clinical study using siddha medicine for Autism spectrum disorder

Phase II Non Randomized Clinical Study In The Management Of Maantha Sanni (Autism Spectrum Disorder) With The Validation Of Siddha Trial Drug Maantha Kuligai As Internal Medicine And Sanni Maantha Pugai As (External) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069064

Enrollment

Registered

2024-06-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F988- Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence

Interventions

Intervention1: Maantha Kuligai (internal) and Sanni Maantha Pugai(external): Maantha Kuligai 1( 145mg)-to 2(290mg) tablet(kuligai) with Hotwater twice a day for 48 days and External Fumigation of Sann

Eligibility

Inclusion criteria

Inclusion criteria: Children have lack of eye contact Lack of response Repetitive and restrictive behavior Unawareness of natural urges Acquired speech or lost it Unusual sensitive to sensory stimuli

Exclusion criteria

Exclusion criteria: Children above 12 years Children below 2 years Severe and recurrent seizure ADHD Cerebral palsy Infantile hemiplegia Congenital anomalies

Design outcomes

Primary

Measure	Time frame
It is mainly assessed by reduction in clinical symptomsTimepoint: 48 Days	—

Secondary

Measure	Time frame
it is assessed by comparing sensory function connecting parameters social interactions adaptive behavior language communication domainsTimepoint: 48 Days	—

Countries

India

Contacts

Public ContactDr C Shanmuga Priya

Government Siddha Medical College Arumbakkam Chennai 106

cspriya2004@gmail.com9445661808

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026